Novavax (NVAX) Receiving Somewhat Positive Media Coverage, Analysis Finds
News headlines about Novavax (NASDAQ:NVAX) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novavax earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7727897102283 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Novavax Inc (NVAX) Technical Fundamentals and Valuation – ExpertGazette (expertgazette.com)
- Novavax, Inc. (NVAX) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Novavax (finance.yahoo.com)
- Equities Analysts Set Expectations for Novavax, Inc.’s FY2017 Earnings (NVAX) (americanbankingnews.com)
- Novavax’s (NVAX) Neutral Rating Reaffirmed at Seaport Global Securities (americanbankingnews.com)
Shares of Novavax (NASDAQ NVAX) traded up 1.72% during midday trading on Thursday, reaching $1.18. The company had a trading volume of 4,062,963 shares. Novavax has a 12-month low of $0.73 and a 12-month high of $1.78. The company has a 50 day moving average of $1.14 and a 200 day moving average of $1.07. The firm’s market capitalization is $342.08 million.
Novavax (NASDAQ:NVAX) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The business’s revenue for the quarter was up 168.0% on a year-over-year basis. During the same period last year, the firm posted ($0.29) earnings per share. Analysts anticipate that Novavax will post ($0.62) EPS for the current year.
A number of research firms have recently commented on NVAX. Seaport Global Securities reiterated a “neutral” rating on shares of Novavax in a research note on Friday, October 6th. Zacks Investment Research cut Novavax from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. BidaskClub upgraded Novavax from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Ladenburg Thalmann Financial Services upgraded Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price on the stock in a research note on Wednesday, August 9th. Finally, Chardan Capital reiterated a “neutral” rating and set a $1.50 target price on shares of Novavax in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the stock. Novavax currently has a consensus rating of “Hold” and a consensus price target of $3.05.
In other Novavax news, Director James F. Young sold 175,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.00% of the company’s stock.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.